KEAP1-NFE2L2 Mutations in NSCLC: Increased Awareness Needed. Reply to "KEAP1-NFE2L2-Mutant NSCLC and Immune Checkpoint Inhibitors: A Large Database Analysis"

Affiliations

¹ Division of Medical Oncology 2, Istituto di Ricovero e Cura a Carattere Scientifico Regina Elena National Cancer Institute, Rome, Italy.
² Medical Oncology Unit, Department of Clinical and Molecular Medicine, Sant'Andrea Hospital, "Sapienza" University of Rome, Rome, Italy.
³ Division of Medical Oncology 2, Istituto di Ricovero e Cura a Carattere Scientifico Regina Elena National Cancer Institute, Rome, Italy. Electronic address: maugeri.marcello@gmail.com.

Free article

Comment

Marco Mazzotta et al. J Thorac Oncol. 2020 Jun.

Free article

. 2020 Jun;15(6):e87-e88.

doi: 10.1016/j.jtho.2020.03.024.

¹ Division of Medical Oncology 2, Istituto di Ricovero e Cura a Carattere Scientifico Regina Elena National Cancer Institute, Rome, Italy.
² Medical Oncology Unit, Department of Clinical and Molecular Medicine, Sant'Andrea Hospital, "Sapienza" University of Rome, Rome, Italy.
³ Division of Medical Oncology 2, Istituto di Ricovero e Cura a Carattere Scientifico Regina Elena National Cancer Institute, Rome, Italy. Electronic address: maugeri.marcello@gmail.com.

No abstract available

Comment on

KEAP1-NFE2L2-Mutant NSCLC and Immune Checkpoint Inhibitors: A Large Database Analysis.
Zhang C, Zhang C, Li J, Wang H. Zhang C, et al. J Thorac Oncol. 2020 Jun;15(6):e85-e86. doi: 10.1016/j.jtho.2020.02.027. J Thorac Oncol. 2020. PMID: 32471565 No abstract available.